JPM2018: $15bn Market Opp Awaits Boston Scientific, Forecasts Mahoney
Executive Summary
Boston Scientific CEO and chairman Mike Mahoney provided a positive preliminary Q4 earnings outlook during his presentation at the JP Morgan HealthCare Conference on Jan. 9, and outlined plans for the medical device giant's growth for 2018 and beyond, including a $15bn market opportunity between 2018 and 2021.
You may also be interested in...
Global Approvals Analysis: Emerging Markets Drive Volume Of OUS Approvals
The numbers of medical device approvals were up in most regions outside the US and the biggest surge, by percentage, was in approvals from emerging markets and the so-called BRIC countries. It remains to be seen if the trend will continue in 2018, but many companies are already counting on important non-US approvals coming in the next year.
Market Intel: Pain Management II: Competition Intensifies For Spinal Cord Stim Market's Big Three
In the global pain management market, spinal cord stimulation (SCS) systems are expected to continue to be the fastest-growing segment with increasing competition among device manufacturers to develop innovative, targeted therapies. In this second article of a two-part series, we'll discuss the competitive landscape in the SCS market, the key players, emerging companies and their respective technologies.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.